Maxim Group Reiterates “Buy” Rating for Atossa Genetics (ATOS)

Share on StockTwits

Maxim Group reissued their buy rating on shares of Atossa Genetics (NASDAQ:ATOS) in a research report report published on Wednesday. The brokerage currently has a $5.00 price objective on the stock.

“Atossa announced that the preliminary results (PK, tolerability, safety) reported in 3Q18 in the P1 study of topical Endoxifen in male healthy subjects are now final. The company is awaiting the completion of an ongoing P2 study in women with mammographic breast density (MBD, expected 2Q19) to determine the next steps clinically for developing topical Endoxifen in men with breast health issues, including gynecomastia.”,” Maxim Group’s analyst wrote.

ATOS stock traded down $0.07 during midday trading on Wednesday, reaching $1.36. 311,577 shares of the company’s stock traded hands, compared to its average volume of 2,580,248. Atossa Genetics has a 52-week low of $0.80 and a 52-week high of $10.68.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.01. As a group, research analysts predict that Atossa Genetics will post -4.31 earnings per share for the current year.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Further Reading: What is the yield curve?

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brightcove  Raised to Buy at Zacks Investment Research
Brightcove Raised to Buy at Zacks Investment Research
Zacks Investment Research Upgrades A-Mark Precious Metals  to “Buy”
Zacks Investment Research Upgrades A-Mark Precious Metals to “Buy”
ARRIS International  Lowered to Buy at BidaskClub
ARRIS International Lowered to Buy at BidaskClub
Maxim Group Reiterates “Buy” Rating for Atossa Genetics
Maxim Group Reiterates “Buy” Rating for Atossa Genetics
Dragonchain Reaches Market Capitalization of $19.71 Million
Dragonchain Reaches Market Capitalization of $19.71 Million
$216.85 Million in Sales Expected for Unit Co.  This Quarter
$216.85 Million in Sales Expected for Unit Co. This Quarter


Leave a Reply

© 2006-2019 Ticker Report